Ikena Oncology (IKNA) Competitors

Ikena Oncology logo
$1.53 +0.07 (+4.79%)
Closing price 04:00 PM Eastern
Extended Trading
$1.54 +0.01 (+0.98%)
As of 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IKNA vs. FDMT, BNTC, LFVN, ITOS, DSGN, ACIU, ELDN, MNPR, AQST, and URGN

Should you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include 4D Molecular Therapeutics (FDMT), Benitec Biopharma (BNTC), LifeVantage (LFVN), iTeos Therapeutics (ITOS), Design Therapeutics (DSGN), AC Immune (ACIU), Eledon Pharmaceuticals (ELDN), Monopar Therapeutics (MNPR), Aquestive Therapeutics (AQST), and UroGen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry.

Ikena Oncology vs.

4D Molecular Therapeutics (NASDAQ:FDMT) and Ikena Oncology (NASDAQ:IKNA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, community ranking, institutional ownership, valuation and dividends.

In the previous week, 4D Molecular Therapeutics had 10 more articles in the media than Ikena Oncology. MarketBeat recorded 13 mentions for 4D Molecular Therapeutics and 3 mentions for Ikena Oncology. Ikena Oncology's average media sentiment score of 0.50 beat 4D Molecular Therapeutics' score of 0.03 indicating that Ikena Oncology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
4D Molecular Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ikena Oncology
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 75.0% of Ikena Oncology shares are owned by institutional investors. 7.3% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 5.9% of Ikena Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

4D Molecular Therapeutics has a beta of 2.81, suggesting that its stock price is 181% more volatile than the S&P 500. Comparatively, Ikena Oncology has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.

4D Molecular Therapeutics presently has a consensus target price of $32.13, indicating a potential upside of 606.04%. Ikena Oncology has a consensus target price of $3.00, indicating a potential upside of 105.48%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe 4D Molecular Therapeutics is more favorable than Ikena Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4D Molecular Therapeutics
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60
Ikena Oncology
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

4D Molecular Therapeutics received 22 more outperform votes than Ikena Oncology when rated by MarketBeat users. Likewise, 67.53% of users gave 4D Molecular Therapeutics an outperform vote while only 58.82% of users gave Ikena Oncology an outperform vote.

CompanyUnderperformOutperform
4D Molecular TherapeuticsOutperform Votes
52
67.53%
Underperform Votes
25
32.47%
Ikena OncologyOutperform Votes
30
58.82%
Underperform Votes
21
41.18%

4D Molecular Therapeutics' return on equity of -28.00% beat Ikena Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
4D Molecular TherapeuticsN/A -28.00% -26.16%
Ikena Oncology N/A -36.88%-33.08%

Ikena Oncology has lower revenue, but higher earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Ikena Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D Molecular Therapeutics$20.72M10.15-$100.84M-$2.85-1.60
Ikena Oncology$9.16M7.69-$68.17M-$1.23-1.19

Summary

4D Molecular Therapeutics beats Ikena Oncology on 13 of the 17 factors compared between the two stocks.

Get Ikena Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IKNA vs. The Competition

MetricIkena OncologyBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$69.97M$3.11B$5.77B$9.15B
Dividend YieldN/A1.79%5.32%4.00%
P/E Ratio-1.1916.9960.3015.12
Price / Sales7.69307.59982.3673.90
Price / CashN/A192.7646.0938.87
Price / Book0.413.975.125.00
Net Income-$68.17M-$40.60M$113.24M$222.75M
7 Day Performance0.69%-3.69%-1.44%-1.01%
1 Month Performance-5.19%0.94%4.80%4.04%
1 Year Performance14.96%-6.91%25.20%21.71%

Ikena Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IKNA
Ikena Oncology
3.5132 of 5 stars
$1.53
+4.8%
$3.00
+96.1%
+6.6%$73.84M$9.16M-1.2470Short Interest ↓
News Coverage
FDMT
4D Molecular Therapeutics
3.0263 of 5 stars
$5.93
+5.9%
$38.56
+550.2%
-83.7%$274.14M$20.72M-2.08120Analyst Forecast
BNTC
Benitec Biopharma
2.6996 of 5 stars
$11.80
+2.7%
$24.43
+107.0%
+257.9%$274.00M$80,000.000.0020
LFVN
LifeVantage
3.9518 of 5 stars
$21.63
+2.2%
$30.50
+41.0%
+198.8%$270.81M$200.16M67.60260Insider Trade
Short Interest ↑
Gap Down
ITOS
iTeos Therapeutics
3.155 of 5 stars
$7.37
-2.3%
$22.25
+201.9%
-32.8%$269.26M$35M-2.3490Short Interest ↑
DSGN
Design Therapeutics
1.8453 of 5 stars
$4.72
-2.7%
$7.00
+48.3%
+53.3%$267.25MN/A-5.5540Positive News
ACIU
AC Immune
1.739 of 5 stars
$2.70
-1.8%
$12.00
+344.4%
-16.6%$267.14M$16.48M-5.87140News Coverage
Positive News
ELDN
Eledon Pharmaceuticals
2.2642 of 5 stars
$4.46
-1.3%
$12.50
+180.3%
+157.1%$266.44MN/A-2.2210Short Interest ↑
Analyst Revision
MNPR
Monopar Therapeutics
1.5821 of 5 stars
$43.55
-0.9%
$43.00
-1.3%
+2,952.6%$265.74MN/A-22.1110Analyst Revision
AQST
Aquestive Therapeutics
2.3605 of 5 stars
$2.89
-4.3%
$11.00
+280.6%
+22.4%$263.51M$50.58M-6.42160Short Interest ↓
News Coverage
URGN
UroGen Pharma
3.8468 of 5 stars
$11.21
+1.8%
$43.70
+289.8%
-46.3%$262.87M$82.71M-3.56200Analyst Forecast
News Coverage

Related Companies and Tools


This page (NASDAQ:IKNA) was last updated on 2/13/2025 by MarketBeat.com Staff
From Our Partners